Omnibus claims are now effectively prohibited following the Raising the Bar amendments, however a great many patents including such claims have been granted. The Full Federal Court decision,GlaxoSmithKline Australia Pty Ltd v Reckitt Benckiser Healthcare (UK) Ltd [2016] FCAFC 90, provides some welcome guidance on how such claims should be construed. At trial, it had …
>> Read more